{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:03:03Z","timestamp":1759104183928,"version":"3.44.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,19]]},"abstract":"<jats:p>Chronic pain, including neuropathic pain (NP), significantly affects quality of life in 7% to 10% of the general population. The prevalence of NP is rising owing to factors such as aging, obesity, and enhanced cancer survival rates. Effective management of NP is essential to improve patient outcomes. This study aimed to assess the safety and effectiveness of controlled-release (CR) pregabalin in Korean patients with peripheral NP . An open-label, non-comparative, multicenter study was conducted with 623 participants across 18 institutions. The patients received pregabalin CR as part of their routine treatment. Safety and efficacy data were collected over 12 weeks. Pain severity was assessed using the 11-point numeric rating scale (0\u2005=\u2005no pain, 10\u2005=\u2005worst imaginable pain), and sleep interference was assessed using an 11-point Likert scale (0\u2005=\u2005did not interfere, 10\u2005=\u2005unable to sleep). Safety was evaluated through adverse event (AE) reporting. Among the 617 participants evaluated for safety, 6.32% reported AEs, primarily dizziness and somnolence. Serious AEs were rare (0.32%). The efficacy analysis included 363 participants, with significant reductions in daily pain (from 5.05\u2005\u00b1\u20052.41 to 3.16\u2005\u00b1\u20052.26, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.0001) and sleep interference scores (from 2.32\u2005\u00b1\u20052.70 to 1.42\u2005\u00b1\u20052.18, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.0001) at week 12. Both the patients\u2019 and clinicians\u2019 global impressions demonstrated meaningful improvements in over 26% of the participants. The efficacy was reduced in patients with a medical history and in those receiving high doses (&gt;165\u2005mg\/d). Pregabalin CR effectively reduced NP and sleep interference, with a manageable safety profile. These findings support the use of this drug as first-line treatment for NP. Personalized treatment and continuous monitoring are recommended to optimize patient outcomes.<\/jats:p>","DOI":"10.1097\/md.0000000000044813","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:03:36Z","timestamp":1758575016000},"page":"e44813","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety and effectiveness of pregabalin controlled-release in Korean patients with peripheral neuropathic pain: A post-marketing surveillance data"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8067-2135","authenticated-orcid":false,"given":"Seong-il","family":"Oh","sequence":"first","affiliation":[{"name":"Department of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea"},{"name":"Formerly, Inje University Busan Paik Hospital, Busan, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Hoon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Young","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chonbuk National University College of Medicine, Jeonju, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee-Youn","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Young","family":"Kang","sequence":"additional","affiliation":[{"name":"Jangsarang Internal Medicine Hospital, Asan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Bum","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Wan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Yonsei University College of Medicine, Seoul, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250928","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","article-title":"Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment.","volume":"10","author":"Breivik","year":"2006","journal-title":"Eur J Pain"},{"key":"R2-20250928","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1152\/physrev.00045.2019","article-title":"Neuropathic pain: from mechanisms to treatment.","volume":"101","author":"Finnerup","year":"2021","journal-title":"Physiol Rev"},{"key":"R3-20250928","first-page":"CD007076","article-title":"Pregabalin for neuropathic pain in adults.","volume":"1","author":"Derry","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-20250928","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00702-020-02145-7","article-title":"Challenges of neuropathic pain: focus on diabetic neuropathy.","volume":"127","author":"Rosenberger","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"R5-20250928","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","article-title":"Neuropathic pain in the general population: a systematic review of epidemiological studies.","volume":"155","author":"Van Hecke","year":"2014","journal-title":"Pain"},{"key":"R6-20250928","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1474-4422(10)70143-5","article-title":"Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment.","volume":"9","author":"Baron","year":"2010","journal-title":"Lancet Neurol"},{"key":"R7-20250928","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain.","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R8-20250928","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Res Manag"},{"key":"R9-20250928","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/11589370-000000000-00000","article-title":"Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study.","volume":"31","author":"Anastassiou","year":"2011","journal-title":"Clin Drug Investig"},{"key":"R10-20250928","doi-asserted-by":"crossref","first-page":"e1066","DOI":"10.1097\/PR9.0000000000001066","article-title":"Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank.","volume":"8","author":"Baskozos","year":"2023","journal-title":"Pain Rep"},{"key":"R11-20250928","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3988\/jcn.2020.16.1.124","article-title":"Comparison of neuropathic pain in neuromyelitis optica spectrum disorder and multiple sclerosis.","volume":"16","author":"Hyun","year":"2020","journal-title":"J Clin Neurol"},{"key":"R12-20250928","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1093\/pm\/pnz075","article-title":"A comprehensive algorithm for management of neuropathic pain.","volume":"20","author":"Bates","year":"2019","journal-title":"Pain Med"},{"key":"R13-20250928","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"R14-20250928","first-page":"CD007076","article-title":"Pregabalin for acute and chronic pain in adults.","author":"Moore","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-20250928","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40261-014-0211-4","article-title":"Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies.","volume":"34","author":"Chew","year":"2014","journal-title":"Clin Drug Investig"},{"key":"R16-20250928","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/AJP.0000000000000445","article-title":"Efficacy and safety of once-daily controlled-release pregabalin for the treatment of patients with postherpetic neuralgia.","volume":"33","author":"Huffman","year":"2017","journal-title":"Clin J Pain"},{"key":"R17-20250928","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/epi.12690","article-title":"Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial.","volume":"55","author":"French","year":"2014","journal-title":"Epilepsia"},{"key":"R18-20250928","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/AJP.0000000000001028","article-title":"Efficacy and safety of a new sustained-release pregabalin formulation compared with immediate-release pregabalin in patients with peripheral neuropathic pain: a randomized noninferiority phase 3 trial.","volume":"38","author":"Han","year":"2022","journal-title":"Clin J Pain"},{"key":"R19-20250928","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00325481.2020.1857992","article-title":"Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration.","volume":"133","author":"Freynhagen","year":"2021","journal-title":"Postgrad Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:03:41Z","timestamp":1759046621000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":19,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044813","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2025-06-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}